Nutcracker Therapeutics Announces Publication in ACS Nano Demonstrating the Therapeutic Viability of Nutshell® Delivery Vehicles
August 7, 2024
EMERYVILLE, Calif., August 7, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced the publication of its latest peer-reviewed paper, which explores the fundamental aspects of its Nutshell® platform of peptoid-based mRNA delivery vehicles. The paper, published in ACS Nano, outlines the design […]
EMERYVILLE, Calif., June 5, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, recently presented a poster on NTX-472, its new preclinical drug candidate for B cell lymphoma, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Monoclonal antibody immunotherapies can […]
EMERYVILLE, Calif., May 15, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced it will introduce its new preclinical drug candidate, NTX-472, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago from May 31 to June 4. […]
EMERYVILLE, Calif., May 15, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today detailed data presented by its partners at the University of California, San Francisco (UCSF) on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470. […]
Nutcracker Therapeutics Demonstrates Enhanced Functional Activity of Prostate Cancer Candidate NTX-470 at the 2024 AACR Annual Meeting
April 11, 2024
EMERYVILLE, Calif., April 11, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data for the company’s mRNA drug candidate for prostate cancer, […]
Nutcracker Therapeutics to Present Data on mRNA Drug Candidate and Immunomodulatory Cytokine at AACR 2024
March 18, 2024
EMERYVILLE, Calif., March 12, 2024 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced that two poster presentations highlighting the company’s RNA therapeutics pipeline will be introduced at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The first presentation entails LIGHT, an […]
Nutcracker Therapeutics Named Industry Veteran Samuel Deutsch as Chief Scientific Officer
January 8, 2024
EMERYVILLE, Calif., January 8, 2024 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary platform, today announced the promotion of Samuel Deutsch, Ph.D., as the company’s chief scientific officer (CSO). Dr. Deutsch has been a part of the Nutcracker team since its inception, and previously served as its […]
Nutcracker Therapeutics Demonstrates Anti-tumor Responses of Two Preclinical mRNA Drug Candidates at 2023 SITC Annual Meeting
November 7, 2023
EMERYVILLE, Calif., November 7, 2023 – Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today presented preclinical data for two of its therapeutic candidates: its latest therapeutic candidate, NTX-471, which targets CD47; and the company’s lead mRNA candidate targeting human papillomavirus (HPV)-driven tumors, NTX-250. These data […]
EMERYVILLE, Calif., November 1, 2023 — Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, today announced two poster presentations: one on the company’s lead mRNA therapeutic candidate, NTX-250, which targets human papillomavirus (HPV)-driven cancers; the other on its latest therapeutic candidate, NTX-471, which targets CD47 and […]
For inquiries, please visit our Contact Page.